Component,HTAN Participant ID,Treatment or Therapy,Treatment Type 1,Treatment Type 2,Treatment Type 3,Treatment Type4,Treatment Effect,Treatment Outcome,Days to Treatment End 1,Days to Treatment End 2,Days to Treatment End 3,Days to Treatment End 4,Treatment Anatomic Site,Days to Treatment Start 1,Days to Treatment Start 2,Days to Treatment Start 3,Days to Treatment Start 4,Initial Disease Status,Regimen or Line of Therapy,Therapeutic Agents 1,Therapeutic Agents 2,Therapeutic Agents 3,Therapeutic Agents 4,Treatment Intent Type,Chemo Concurrent to Radiation,Number of Cycles,Reason Treatment Ended,Treatment Arm,Treatment Dose,Treatment Dose Units,Treatment Effect Indicator,Treatment Frequency,entityId,Uuid
Therapy,HTA1_988,Yes,Chemotherapy,Chemotherapy,Chemotherapy,,,,13026.0,13026.0,13089.0,,,12977,12977.0,13047.0,,,,Doxorubicin Hydrochloride,Cyclophosphamide,Paclitaxel,,,,,,,,,,,syn25958326,ceaa8cf5-7009-4458-9c85-e7e347c04e08
Therapy,HTA1_988,Yes,Chemotherapy,Chemotherapy,Chemotherapy,,,,13728.0,13728.0,13728.0,,,13565,13565.0,13565.0,,,,Cyclophosphamide,Methotrexate,Fluorouracil,,,,,,,,,,,syn25958327,6c815ea5-f619-48ac-b2fe-db68b0e6d8dc
Therapy,HTA1_988,Yes,Other,Immunotherapy (Including Vaccines),,,,,14419.0,14419.0,,,,14375,14375.0,,,,,Other NOS,Pembrolizumab,,,,,,,,,,,,syn25958328,0de7df05-1dac-4dc9-ae3a-a679c95253f0
Therapy,HTA1_988,Yes,Chemotherapy,,,,,,14495.0,,,,,14450,,,,,,Eribulin Mesylate,,,,,,,,,,,,,syn25958329,ec634b4e-1423-43e7-a216-4abccd883508
